Cyclone® IKON
Productive, Adaptive, Effective.
- PET Imaging
- SPECT Imaging
- 64Cu
- 68Ge
- 123I
- 201Tl
- 89Zr
- 18F
- 68Ga
- 124I
- The most adaptive cyclotron
Cyclone® IKON is a variable-energy cyclotron that accelerates protons from 13 to 30 MeV. It offers wide flexibility in both accelerated current and energy, giving you broad freedom to optimize your production.
- High energy, high productivity
Cyclone® IKON is a compact, fully industrial cyclotron designed with advanced automation to deliver reliable, high-throughput isotope production.
- Energy
13 to 30 MeV
- Cyclotron dimensions
2.2 x 2.2 x 1.46 m
- Target
High power 30 MeV or compact PET solid, liquid, gas
- Vault dimensions
6 x 8 x 3 m (with long beam line)
- Exit ports
2 x 3 exits (2 with beam line variable energy, one fixed 18 MeV)
- Beam lines
Up to 4 long beam lines
- Production power
Up to 1500 µA
- Productive
Light & compact, Cyclone® IKON makes no compromise on power with up to 1500 µA extracted proton beam current.
- Adaptive
Cyclone® IKON offers a large energy span (13 to 30 MeV) with full current capacity to enable the large-scale and high-purity production of isotopes.
- Effective
IBA offers complete radioisotope production solutions, from the target irradiation system to the purified end-product allowing you to have full control of your production process.
- Ready when you are
IBA promises that your cyclotron is available when you are ready with your building.
Interested to learn more about the Cyclone® IKON?
Download product information
Find out everything you need to know about the Cyclone® IKON.
You don’t only have to take our word for it. Here is what others say about the Cyclone® IKON.
We've selected IBA because of the reliability of its equipment
“We've selected IBA because of the reliability of its equipment. It has the most compact and efficient high energy cyclotron on the market."
IBA high-energy cyclotrons installed across the world
- 26/05/2025
- Curium
Successful start of operations of its Cyclone® IKON at Curium, St. Louis, US !Its Cyclone® IKON, CE marked, offering the largest energy spectrum for PET and SPECT isotopes, is installed on its North American headquarters and historical St. Louis site in United States.
With its high energy cyclotron, Curium secures a reliable large-scale production of novel radioisotopes to ensure the development and distribution of radiopharmaceutical solutions for patients with life-threatening diseases worldwide.
Congratulations to Curium Pharma for this important achievement !
- 21/05/2025
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in TaiwanThe Cyclone® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV
Louvain-la-Neuve, Belgium, May 21, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Pharm Bio is a manufacturer and provider of medical isotopes used for oncology diagnosis and therapy.
The radioisotopes production center will be equipped with a Cyclone® IKON and will include beam lines, solid targets for SPECT and PET isotopes, as well as radiochemistry solutions. The new PET Pharm Bio radiopharmacy will also benefit from IBA IntegraLab® design and third parties integration services ensuring the full GMP compliance of this production center.
This new GMP radiopharmacy will be used to produce novel radiopharmaceuticals for applications in theranostics and targeted therapies, including Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123, Thalium-201, Zirconium-89 and Copper-64.
The typical end-user price for a Cyclone® IKON solution is between EUR 10 and 15 million, depending on options and associated equipment.
John Yang, Chairman of PET Pharm Bio Taiwan R.O.C., said: “With IBA Cyclone® IKON 30 MeV as the backbone, which makes the production of numerous theranostic radiopharmaceuticals possible, PET Pharm Bio will be quickly propelled into a new territory previously not existing in Taiwan and Southeast Asia. As the largest radiopharmaceutical GMP manufacturer in Taiwan, partnering with IBA elevates us to the rank of developers of innovative radiopharmaceuticals targeting not only markets in Taiwan, but globally.”
Charles Kumps, President of IBA RadioPharma Solutions, added: “We are pleased to partner with PET Pharm Bio and support them in their ambition to produce and deliver key radiopharmaceuticals to advance nuclear medicine applications in the region. There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. The acquisition of IBA’s Cyclone® IKON solution will enable PET Pharm Bio to leverage a versatile and high-power system at minimal running costs.”
- 30/08/2022
CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in ChinaLouvain-La-Neuve, Belgium, August 30, 2022 –IBA(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announced it has signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million.
The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities.
Jiming Cai, General Manager of CNRT, commented: “We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first Cyclone® IKON cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.”
Bruno Scutnaire, President of IBA RadioPharma Solutions, added: “There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.”